> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# OSE Using Artificial Intelligence to Aid Drug Surveillance
- URL: https://www.fdaweb.com/ose-using-artificial-intelligence-to-aid-drug-surveillance/
- Published: 2022-06-28T12:00:00.000Z
- Updated: 2026-09-14T17:50:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152188

The CDER Office of Surveillance and Epidemiology (OSE) has developed and is using an Information Visualization Platform (InfoVIP) incorporating artificial intelligence (AI) and advanced visualizations to support OSE safety reviewers as they examine data or content to discover deeper insights, make predictions, or generate recommendations to support postmarket safety surveillance. OSE regulatory science staffer **Oanh Dang** [says](https://www.fda.gov/drugs/news-events-human-drugs/cder-conversation-information-visualization-platform-infovip-cders-new-artificial-intelligence?ref=fdaweb.com) the volume and complexity of individual case safety reports collected by the FDA Adverse Event Reporting System led to the development of InfoVIP to increase efficiency in the labor-intensive case report review and evaluation process.

She says InfoVIP incorporates natural language processing, machine learning, and advanced data visualizations and is used as a decision-support software tool to help safety reviewers, analysts, and decision-makers make better and faster decisions.

According to Dang, within InfoVIP, human experts can readily locate the case safety report data that the AI tool extracted to verify the accuracy of the natural language processing-derived timeline of events and the classification of a report as high- or low-quality. “AI technologies support and strengthen InfoVIP to develop insights from data for safety reviewers to consider, validate, and ultimately use, to inform decisions about the safety of drugs and therapeutic biologics,” she concludes.